FPS
TVRD

Fieldpoint Private Securities’s Tvardi Therapeutics TVRD Stock Holding History

Fieldpoint Private Securities’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$1K Hold
3
– – ﹤0.01% 1453
2022
Q1 		$1K Buy
+3
New +$1.23K ﹤0.01% 1634

Other funds holding TVRD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fieldpoint Private Securities's TVRD Position: Q2 2022 in Review

Fieldpoint Private Securities held its Tvardi Therapeutics (TVRD) position steady in Q2 2022 at 3 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1453.

Fieldpoint Private Securities first reported a position in TVRD in Q1 2022 and has held it in 2 quarters since. 179 funds tracked by Wall St. Rank hold TVRD as of Q2 2022.

  • Fieldpoint Private Securities held 3 shares of Tvardi Therapeutics worth $1K as of Q2 2022.
  • Fieldpoint Private Securities left its Tvardi Therapeutics share count unchanged in Q2 2022.
  • Tvardi Therapeutics made up ﹤0.01% of Fieldpoint Private Securities's portfolio in Q2 2022, its #1453 holding.
  • Fieldpoint Private Securities first reported a position in Tvardi Therapeutics in Q1 2022 and has held it in 2 quarters since.
  • 179 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2022.

Based on Fieldpoint Private Securities's 13F filing for Q2 2022, filed 5 Aug 2022.